Analysts expect Kadmon Holdings Inc (NYSE:KDMN) to report earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Kadmon’s earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.24). Kadmon posted earnings per share of ($0.24) in the same quarter last year, which indicates a positive year over year growth rate of 4.2%. The company is scheduled to issue its next earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Kadmon will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.46). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.54) per share, with EPS estimates ranging from ($0.86) to ($0.18). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Kadmon.

Kadmon (NYSE:KDMN) last posted its quarterly earnings results on Thursday, August 9th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.50. The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.90 million.

Several research firms have commented on KDMN. ValuEngine raised Kadmon from a “hold” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a report on Thursday, October 11th. WBB Securities raised Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price target for the company in a report on Wednesday, October 17th. Finally, HC Wainwright set a $25.00 target price on Kadmon and gave the stock a “buy” rating in a report on Monday, August 13th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $11.43.

Kadmon stock opened at $2.64 on Wednesday. The company has a market capitalization of $306.50 million, a price-to-earnings ratio of -1.86 and a beta of 3.57. Kadmon has a 12 month low of $1.88 and a 12 month high of $5.86.

Several institutional investors and hedge funds have recently modified their holdings of the company. AE Wealth Management LLC raised its holdings in shares of Kadmon by 3.7% in the 2nd quarter. AE Wealth Management LLC now owns 529,212 shares of the company’s stock worth $2,112,000 after buying an additional 18,750 shares in the last quarter. American International Group Inc. raised its holdings in shares of Kadmon by 46.2% in the 3rd quarter. American International Group Inc. now owns 66,148 shares of the company’s stock worth $221,000 after buying an additional 20,894 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Kadmon in the 1st quarter worth approximately $106,000. Voya Investment Management LLC acquired a new position in shares of Kadmon in the 2nd quarter worth approximately $101,000. Finally, Metropolitan Life Insurance Co. NY acquired a new position in shares of Kadmon in the 2nd quarter worth approximately $105,000. 69.65% of the stock is owned by institutional investors and hedge funds.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

See Also: What are CEFs?

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.